Hormonal
Gut microbiota composition directly modulates insulin sensitivity in Toll-like receptor 2 (TLR2) knockout mice, where a specific microbial profile (increased Firmicutes, decreased Bifidobacterium) induces insulin resistance, glucose intolerance, and obesity, effectively reversing the genetically protected phenotype.
Your genetic makeup does not guarantee metabolic health. Even if you have a genetic profile that typically protects against insulin resistance, your gut microbiota can override this protection. Maintaining a healthy gut microbiome through diet and lifestyle is crucial for insulin sensitivity, regardless of your genetic background.
Our results indicate that the gut microbiota per se can subvert a genetically predetermined condition previously described as being protective towards obesity and insulin resistance into a phenotype associated with weight gain and its complications, such as glucose intolerance and diabetes.
Why this rating
High-quality mechanistic evidence in mice with multiple validation steps (antibiotics, transplantation, inhibitors), but translational relevance to humans requires caution.
Source
Gut Microbiota Is a Key Modulator of Insulin Resistance in TLR 2 Knockout Mice
Andréa M. Caricilli et al. · PLoS Biology · 2011
DOI 10.1371/journal.pbio.1001212
More from this paper
- Restoring or altering gut microbiota composition via broad-spectrum antibiotics or microbiota transplantation can reverse insulin resistance and metabolic syndrome symptoms in TLR2 knockout mice.Good
- Increased gut permeability (leaky gut) and elevated serum LPS levels are key mechanisms by which altered gut microbiota induces insulin resistance in TLR2 knockout mice.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →